Skip to main content

Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.

Publication ,  Journal Article
Vaidyanathan, G; Affleck, DJ; Zalutsky, MR
Published in: J Nucl Med
April 1995

UNLABELLED: This study evaluates the potential utility of 4-[18F]fluoro-3-iodobenzylguanidine ([18F]FIBG) as an MIBG analog. METHODS: In vitro assays of tracer binding were carried out using the SK-N-SH human neuroblastoma cell line in a paired-label format to compare [18F]FIBG directly with no-carrier-added [125I]MIBG. To ascertain whether [18F]FIBG, like MIBG, is taken up by the uptake-1 mechanism, the effects of desipramine, norepinephrine, and carrier MIBG and FIBG on cell binding were determined. Preincubation with ouabain and incubation at 4 degrees C was used to evaluate the energy-dependence of [18F]FIBG uptake by SK-N-SH cells. The tissue distribution of [18F]FIBG in mice was compared with no-carrier-added [125I]MIBG in a paired-label study. RESULTS: In paired-label binding studies, the percent binding of [18F]FIBG to neuroblastoma cells remained constant over a three-log activity range and the level was somewhat higher than that of no-carrier-added [125I]MIBG. Binding was blocked by desipramine, norepinephrine, carrier MIBG and FIBG, ouabain and by incubating at 4 degrees C, suggesting that [18F]FIBG is taken up by the uptake-1 mechanism. Radiation dosimetry calculations suggest that higher doses of [18F]FIBG, unlike [124I]MIBG, could be administered to patients. CONCLUSION: These in vitro and in vivo evaluations show that [18F]FIBG is an excellent analog of MIBG, suggesting that [18F]FIBG should be further evaluated for use in PET imaging of neuroendocrine tumors and cardiac abnormalities.

Duke Scholars

Published In

J Nucl Med

ISSN

0161-5505

Publication Date

April 1995

Volume

36

Issue

4

Start / End Page

644 / 650

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Tomography, Emission-Computed
  • Tissue Distribution
  • Radiation Dosage
  • Nuclear Medicine & Medical Imaging
  • Mice, Inbred BALB C
  • Mice
  • Iodobenzenes
  • Iodine Radioisotopes
  • In Vitro Techniques
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vaidyanathan, G., Affleck, D. J., & Zalutsky, M. R. (1995). Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med, 36(4), 644–650.
Vaidyanathan, G., D. J. Affleck, and M. R. Zalutsky. “Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.J Nucl Med 36, no. 4 (April 1995): 644–50.
Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med. 1995 Apr;36(4):644–50.
Vaidyanathan, G., et al. “Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.J Nucl Med, vol. 36, no. 4, Apr. 1995, pp. 644–50.
Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med. 1995 Apr;36(4):644–650.

Published In

J Nucl Med

ISSN

0161-5505

Publication Date

April 1995

Volume

36

Issue

4

Start / End Page

644 / 650

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Tomography, Emission-Computed
  • Tissue Distribution
  • Radiation Dosage
  • Nuclear Medicine & Medical Imaging
  • Mice, Inbred BALB C
  • Mice
  • Iodobenzenes
  • Iodine Radioisotopes
  • In Vitro Techniques